Cairn Surgical has submitted a De Novo 510(k) application to the FDA for its Breast Cancer Locator (BCL) System, a patient-specific 3D printed surgical guide.

Cairn Surgical has submitted a De Novo 510(k) application to the FDA for its Breast Cancer Locator (BCL) System, a patient-specific 3D printed surgical guide. The system utilizes supine MRI data to create a custom-fitted device that maps tumor location, size, and shape, aiming to improve surgical precision in breast-conserving procedures. Clinical data supporting the submission indicates that the BCL System achieved negative margins in 94% of patient cases, potentially reducing the need for repeat lumpectomies. CEO David Danielsen confirmed the full clinical trial results will be presented at the American Society of Breast Surgeons annual meeting in April.

This development highlights the growing integration of patient-specific anatomical modeling in oncology, moving beyond standard imaging to physical surgical guidance. By addressing the high rate of margin-related complications in lumpectomies, Cairn Surgical enters a specialized niche within the medical AM market where precision and workflow efficiency are critical. While traditional wire-guided localization remains the standard, the BCL System offers a tangible improvement in spatial orientation during surgery. The company is positioning itself as a provider of high-value, software-driven medical devices that leverage 3D printing to solve specific clinical pain points in the U.S. healthcare system.

Achieving FDA clearance will be the primary hurdle for Cairn Surgical to transition from clinical trials to commercial adoption. The company must demonstrate that its manufacturing workflow can maintain regulatory compliance while scaling to meet the demands of hospital surgical departments. Success will depend on the BCL System's ability to integrate seamlessly into existing surgical workflows without adding significant time or cost to the procedure.